New tablets will replace several types of medicines for cores
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
New tablets for daily use will help to save the lives of millions of people suffering from heart disease. At the George Institute, the experts developed a new drug, which contains several active ingredients (aspirin, statins, a cure for hypertension) that normalize cholesterol and blood pressure. As experts note, the new drug is inexpensive and helps prevent a number of serious diseases, such as stroke, myocardial infarction, etc. The new drug should be taken only once a day, which is convenient for many patients, because people with an increased risk of heart attacks are forced to take a large number of different medications every day. Testing showed that the new drug is more effective than standard methods of treatment of cardiovascular diseases. One tablet is able to replace several drugs.
To test a new drug, scientists studied the health status of more than three thousand patients - cores from Australia, India, Europe, which for a year gave a new drug. A year later, after examining patients, experts noted an improvement in cholesterol and pressure, while adherence to the regimen increased by 43%.
Today, the world's mortality from cardiovascular disease is in the first place. Every year more than 17 million people die from heart attacks. A new drug, which is convenient to take, will reduce the number of deaths from heart diseases. As experts note, by 2025 the death rate may decrease by 25%.
Another research group found a medicinal agent that well resists infectious microorganisms. The detected agent resembles a drug against mycobacterium tuberculosis.
Testing showed that the molecule SQ109 also acts against other proteins that are vital for normal vital activity of parasites, bacteria, fungi. At the same time, the SQ109 does not pose any danger to human health. In addition, SQ109 disrupts the membrane of bacteria, stops the enzymes of the synthesis of menaquinone. All this leads to the fact that permeability of pathogenic microorganisms increases, i.e. The cell remains defenseless and dies.
After the drug was discovered, the scientists were able to develop several analogues SQ109, which in structure and functionality are similar to SQ109, but are more effective and less toxic. Investigation of newly created molecules was carried out on bacteria, fungi, parasites, and also human cells. As a result, one of the new drugs showed efficacy in fighting mycobacteria tuberculosis several times higher than that of the original SQ109. Also among the analogs were drugs that effectively helped with the most severe forms of malaria.
The plus of SQ109 is that there is no evidence of sustainability against it. This problem often occurs during the development of anti-infectious drugs and depends on how many types of pathogenic flora can destroy the drug. In the event that the drug is directed at the destruction of one type of bacteria, the risk of developing resistance increases.
In the near future, scientists plan to test SQ109 against sleeping sickness, Chagas disease, leishmaniasis.
[